Landi Renzo SpA (LNDR) Chart

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed the company's newly-announced research license agreement with Catalent with Proactive's Stephen Gunnion. Buck shared insights into Lisata’s preclinical evaluation of certepetide using Catalent’s SMARTag antibody-drug conjugate (ADC) platform.. She explained that Catalent would assume all R&D costs, while Lisata provides consulting and stands to receive both upfront and potential milestone payments. Certepetide is described as a unique cyclic non-amino acid peptide, designed to bind to receptors commonly found on solid tumors. Upon binding, it transforms to activate a transport mechanism that boosts therapeutic penetration. "It can work with current therapies and emerging therapies," Buck said, emphasizing its compatibility and favorable safety profile. Buck further discussed the growing relevance of ADCs in oncology. She described ADCs as “biological missiles,” targeting tumors while minimizing harm to healthy tissues. When combined with certepetide, ADCs benefit from deeper tumor penetration and potential immunomodulation, making treatment more effective. The company expects initial data from this collaboration before the end of Q2 2025. Positive results could lead to a deeper relationship with Catalent. Visit Proactive's YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #LisataTherapeutics #KristenBuck #Certepetide #AntibodyDrugConjugates #ADC #OncologyInnovation #CancerResearch #Catalent #BiotechNews #TumorTargeting #ImmunoOncology #SMARTagPlatform

Scancell Holdings PLC CEO Phillip L’Huillier joined Proactive's Stephen Gunnion with details of the company’s partnership with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study evaluating the iSCIB1+ DNA cancer vaccine. L’Huillier described the deal as “a very positive endorsement for Scancell and for the medicines that we are developing,” noting that the therapy is showing promise in delivering long-term immune control in advanced melanoma patients. The NHS collaboration enables hospitals to more quickly access and offer the iSCIB1+ therapy as part of the trial, making Scancell the first UK company to partner with the platform and the first to offer a DNA cancer vaccine through it. He explained that the vaccine is given alongside checkpoint inhibitors, currently standard care, to boost response rates and prolong efficacy, especially where standard therapy alone sees limited, short-lived results. L’Huillier confirmed multiple SCOPE study data readouts are expected in 2025, with a larger development phase targeted for 2026. The company is also progressing its Modi-1 peptide vaccine and aims to further develop its GlyMab antibody platform, including the SC134 programme for small cell lung cancer. L’Huillier said his CEO priorities include sticking to development timelines, building strategic partnerships, and preparing the organisation for future phases. For more exclusive biotech interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future updates. #Scancell #CancerVaccine #BiotechNews #iSCIB1 #MelanomaResearch #NHSPartnership #DNAImmunotherapy #Modi1 #ClinicalTrials #OncologyInnovation #InvestorUpdate #ProactiveInvestors

GoviEx Uranium Inc CEO Daniel Major talked with Proactive's Stephen Gunnion about the company’s latest milestone—the submission of a draft Environmental and Social Impact Assessment (ESIA) for its Muntanga uranium project in Zambia. This filing follows the completion of a feasibility study that defined the project’s structure and has triggered the next phase of regulatory review. “We now wait for ZEMA, the Zambian Environmental Management Agency, to come back with their comments,” Major said, expressing confidence in the clean design and minimal environmental issues identified so far. He added that the company hopes to receive approvals in the third or fourth quarter of this year, potentially allowing construction to commence, pending financing. Major also emphasised Muntanga’s strategic position as one of the few near-term uranium projects that could help address an anticipated supply deficit from 2029 onwards. Citing the latest Red Book report, he noted that while uranium resources are ample, there is a shortfall of ready-to-develop projects. He also addressed current uranium pricing, stressing the need for both spot and long-term prices to rise above $80 to incentivise new development. “Prices have got to go higher. And they have to be built,” he said, referring to new uranium projects. For more videos like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #GoviExUranium #UraniumMining #MuntangaProject #NuclearEnergy #ZambiaMining #UraniumPrices #EnergySupply #ESIA #UraniumProjects #ProactiveInvestors

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a pivotal strategic development for the company. Nextech3D.ai has entered into a Letter of Intent to sell up to an 80% equity interest in its spin-out subsidiary, Toggle3D.ai, to TQG Technologies. The proposed transaction not only transitions Toggle3D.ai into its next phase of evolution under new majority ownership, but also provides Nextech3D.ai with a non-dilutive capital infusion of CAD $610,000, strengthening the company’s balance sheet and strategic flexibility without impacting existing shareholder equity. Gappelberg explained that the transaction will be structured in three tranche wuth TQG Technologies acquireing 11 million shares of Toggle3D.ai for CAD $610,000 in cash. Contingent on the closing of TQG’s capital raise, an additional 5 million shares will be purchased for CAD $276,000. The final stage will complete the 80% acquisition through a combination of share purchases and the vending-in of TQG’s strategic assets into Toggle3D.ai. As part of the agreement framework, a non-refundable deposit of CAD $177,000 will be paid by TQG upon the finalization of the deal’s structure by its management. Further milestone-based payments are scheduled to be completed by August 2025. Additionally, Nextech3D.ai stands to receive a performance-based bonus of CAD $710,000 if TQG successfully closes a financing round of at least USD $5 million by that time. The two companies plan to issue a joint public announcement upon the execution of the definitive agreement and will coordinate a co-branded PR campaign to spotlight Toggle3D.ai’s new strategic direction and business roadmap under TQG’s leadership. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #toggle3d TQGtechnologies